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Many claims have been made in recent years regarding the utility of plasma B-type
natriuretic peptide (BNP) concentration measurements in the diagnosis, risk stratifi-
cation and monitoring of patients with heart failure. This paper summarizes the
current evidence and provides guidance for practising clinicians. Overall, plasma BNP
testing appears to be of most value in the diagnostic arena, where it is likely to
improve the performance of non-specialist physicians in diagnosing heart failure. In
clinical practice, BNP testing is best used as a ‘rule out’ test for suspected cases of
new heart failure in breathless patients presenting to either the outpatient or
emergency care settings; it is not a replacement for echocardiography and full
cardiological assessment, which will be required for patients with an elevated BNP
concentration. Although work is ongoing in establishing the ‘normal’ values of BNP,
heart failure appears to be highly unlikely below a plasma concentration of 100 pg/ml.
However, as BNP levels rise with age and are affected by gender, comorbidity and drug
therapy, the plasma BNP measurement should not be used in isolation from the
clinical context.
© 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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Introduction
A growing body of evidence suggests that measurement
of plasma B-type natriuretic peptide (BNP) concen-
trations represents a useful addition to the chest x-ray,
electrocardiogram, and Doppler echocardiography in the
clinical assessment of patients suspected to have heart
failure, both in the outpatient and in the emergency care
settings. In particular, BNP appears to have clinical utility
in excluding a diagnosis of heart failure in patients with
symptoms of breathlessness or fluid retention, and may
provide prognostic information in those with heart failure
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or other cardiac disease. There is also some evidence
that it may prove useful in monitoring therapy for heart
failure.
This paper summarizes the current evidence for the
use of BNP measurement in the diagnosis, risk stratifi-
cation and monitoring of patients with heart failure, and
provides guidance for practising clinicians.
Background
B-type natriuretic peptide (BNP) is one of a family of
structurally similar peptide hormones that also includes
atrial natriuretic peptide (ANP), C-type natriuretic
peptide (CNP), and urodilatin. Both ANP and BNP are
secreted by atrial and ventricular myocytes, although the
major site of production of BNP is the left ventricle.1–5
BNP, which is produced by cleavage of a precursor pro-
tein (proBNP) into BNP and the biologically inactive
peptide NT-proBNP, causes natriuresis, diuresis, vaso-
dilatation and smooth muscle relaxation.6–12 ANP has
similar properties to BNP, but is chiefly produced by the
atria.1,6–8 Plasma concentrations of both BNP and ANP
rise in various pathological states, particularly where
there is increased cardiac chamber wall stretch,2 an
expanded fluid volume (e.g. in heart failure, renal fail-
ure, primary hyperaldosteronism) or reduced clearance
of peptides (renal failure). ANP secretion is by immediate
release from atrial storage granules in response to
atrial stretch, while BNP secretion is controlled at the
transcriptional level, usually requiring a longer-term
stimulus.
Plasma BNP concentrations are raised in patients with
heart failure, rising in line with NYHA class.13 Further-
more, studies have shown that the greater the cardiac
damage the higher the plasma BNP concentration.14
‘Normal’ values of BNP have yet to be fully estab-
lished, although plasma BNP concentrations are known
to be affected by age, gender, renal failure and drug
use, particularly drugs such as diuretics and beta-
blockers.
Practical considerations regarding
natriuretic peptide assays
At present, there are two natriuretic peptide assays
commercially available in both the USA and Europe that
can be used in routine clinical and laboratory practice.
The first is a rapid fluorescence immunoassay for BNP,
which provides results within 15 min on a point-of-care
patient testing device (Biosite Diagnostics, San Diego).15
Results on this device generally correlate well with re-
sults from radioimmunoassay.16 This method may be
particularly attractive in clinical situations where access
to a laboratory is difficult or when a rapid result is
required.
The second is an electrochemiluminescent assay avail-
able for measuring NT-proBNP with a processing time of
only 18 min (Roche Diagnostics GmbH, Basel).17
The reference ranges for BNP and NT-proBNP vary
depending on the assay method employed and the nature
of the control population.18 In general, the plasma BNP
concentration rises with age and may be slightly higher in
women than in men.19,20 A suggested ‘normal’ range for
BNP is 0.5–30 pg/ml (0.15–8.7 pmol/l).21 For NT-proBNP
a suggested reference range is 68–112 pg/ml (8.2–
13.3 pmol/l).22
The suggested decision cut-point for the detection of
heart failure for the BNP point-of-care assay is 100 pg/ml
in those aged more than 55 years. For NT-proBNP the
recommended decision cut points are 100 pg/ml for men
and 150 pg/ml for women in Europe, but 125 pg/ml for
both genders in the USA.
A further laboratory-based assay for BNP is avail-
able currently in Europe only and is manufactured by
Bayer. The decision cut-point for the diagnosis of
heart failure is identical to that of the Biosite
assay—100 pg/ml.
Laboratory vs point of care testing
Whether the assay is performed in a central laboratory
(the NT-proBNP assay) or by point-of-care testing (the
BNP assay) will depend on the level of organization within
the hospital; there are few head-to-head comparisons of
the two assays, and the results of ongoing studies are
awaited.
Measurement in a central laboratory offers the com-
fort of tight quality control and may be preferred since,
at present, acute treatment decisions rarely depend on
the BNP test result. However, for emergency care
patients, the test result should be available within 1 h
of blood collection. Point-of-care testing is justifiable
where the central laboratory cannot provide a test
result within 1 h from blood collection on a 24-h basis,
or where the transportation time of the sample to the
lab is more than one day (in whole blood stored at room
temperature, BNP is stable for up to one day). It is vital
to ensure appropriate training of the individuals who
will carry out the testing, and regular quality control
assessment.
Point-of-care testing is increasingly used in cardio-
vascular medicine as it offers the ability to provide
rapid results and consequently rapid adjustment in
therapy. It is also consistent with the modern approach
to organizing care for patients with stable heart fail-
ure, whereby all investigations are performed and
management decisions are made at a single visit,
which is clearly more convenient for patients as it
potentially reduces the number of follow-up visits
required.
In addition to its demonstrated utility in the emer-
gency care setting, point-of-care testing is likely to be of
particular value for diagnostic purposes in primary care,
where it may find a role in rationalizing demand for
echocardiography services. However, the feasibility of
its use will depend on local cost and reimbursement
considerations.
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BNP and NT-proBNP testing in clinical
practice
Testing for either BNP or NT-proBNP has a number of
possible uses in heart failure practice:
+ Diagnosis
+ Screening for asymptomatic left ventricular dys-
function
+ Risk stratification and prognostication
+ Treatment monitoring.
Diagnosis
Evidence for the role of BNP in the diagnosis of heart
failure has been obtained in both the outpatient and
emergency care settings. The two populations are quite
different: patients admitted acutely are usually more
functionally impaired with shorter duration of symptoms
and the aetiology is more often acute coronary disease.
Among outpatients the symptoms may be milder and of
more insidious onset, making diagnosis more difficult;
only half of patients with a suspected diagnosis of heart
failure have the diagnosis confirmed on fuller assessment
by a cardiologist.23,24 The situation is further com-
pounded by variable primary care access to cardiac inves-
tigations such as echocardiography and to specialists,
both across Europe and within certain countries such as
the UK.
Outpatient/clinic setting
In the population-based Hillingdon Heart Failure Study,
one-third of patients referred to a rapid access clinic by a
primary care physician with a new diagnosis of heart
failure had the diagnosis confirmed on further assess-
ment.25 The diagnostic value of the plasma BNP concen-
tration compared with the clinical opinion of an expert
panel was very high. The area under the receiver-
operating characteristic (ROC) curve for plasma BNP was
0.96, compared with 0.79 for cardiothoracic ratio on
chest X-ray.
Taking a cut-off value of 22 pmol/l (76.4 pg/ml)
combined a very high negative predictive value (98%)
with an acceptable positive predictive value of
70%—with a sensitivity of 97% and specificity of 84%.
Therefore, this study suggests there is a potential for
the BNP test to improve the efficiency of referring
patients for further assessment. The findings of this
study are currently being validated in the multi-
center UK Natriuretic Peptide Diagnosis Study, which
will report in 2003.
Recently, the Natriuretic Peptides in the Community
study of 304 patients presenting to a GP with short-
ness of breath or oedema found that only 25% of cases
met the ESC definition of heart failure.26 When the
GP was given clinical information (ECG, chest X-
ray, echocardiography) the accuracy of the GP diagnosis
improved by 7%, but giving clinical information together
with the NTproBNP test result improved the accuracy
of the diagnosis by 21% (P=0.002). The area under
the ROC curve for plasma NTproBNP was 0.82. The
diagnostic threshold for NTproBNP that combined
optimal sensitivity and specificity for diagnosing heart
failure was 125 pmol/l. For clinical use in the com-
munity, therefore, a recommended diagnostic threshold
of between 100 and 150 pmol/l was thought to be
appropriate.
NTpro-BNP levels may also have some utility when
revisiting a historical diagnosis of heart failure in the
community setting. This was demonstrated in a sample of
103 patients labeled as having heart failure,27 among
whom only 35 were found to have heart failure according
to ESC criteria. NT-proBNP assay gave an AUC of 0.80.
Using an NT-proBNP cut-point of >36 pmol/l gave 100%
sensitivity, 18% specificity, 100% negative predictive
value and 39% positive predictive value in this primary
care setting among patients on treatment for ‘heart
failure’.
Emergency care setting
The accuracy of diagnosis of heart failure by clinical
means and standard testing is often inadequate in the
emergency care setting. In the Breathing Not Properly
(BNP) study, which was conducted in academic centres in
North America and Europe, more than 40% of emergency
room doctors showed significant indecision regarding the
diagnosis when blinded to the BNP values. The plasma
BNP concentration was identified a major independent
predictor of heart failure.28
In this study, using a plasma BNP cutpoint of 100 pg/ml
gave a sensitivity of 90% (95% Confidence interval 88–
92%) and a specificity of 76% (73–79%). BNP was signifi-
cantly more accurate than clinical judgment and
traditional diagnostic methods in identifying patients
with heart failure (81% vs 74%, P=0.0001).29 The pro-
portion of patients in whom the clinician was uncertain of
the diagnosis would have been reduced from 43% to 11%
had the BNP concentration been made available to the
clinician (P=0.0001).
In the United States, the Food and Drug
Administration-approved level of BNP used to separate
heart failure from other causes of dyspnoea is 100 pg/ml
using the point of care testing system from Biosite
Diagnostics. This value was chosen for its 95%
sensitivity in separating NYHA classes I to IV of heart
failure from patients who do not have heart failure.
Pending further work on cut-points, it should remain the
cut-off of choice in patients who present with breathless-
ness; it has a high negative predictive value for heart
failure (whether systolic or diastolic) and therefore will
minimize the risk of a patient with heart failure being
‘missed’.
Large centres experienced in the diagnostic use of
point of care BNP testing may use a more complex algor-
ithm to guide management based on the BNP values,30
recognizing that the probability of heart failure being
present increases steeply as the BNP concentration
rises.
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However, it is important to remember that BNP is
not a stand-alone diagnostic test; it must be used and
interpreted in a wider clinical context, particularly
regarding age and gender. In particular, clinicians must
be aware that several clinical circumstances can alter
the clinical interpretation of BNP concentrations. These
include ischaemia, infarction and renal insufficiency,
which lead to elevation of circulating BNP con-
centrations. In addition, beta-blockade may have a
variable effect on circulating BNP concentrations,
and ACE inhibitors and diuretics will reduce BNP
concentrations.31,32
Practical application
Patients presenting in primary care/outpatient
setting
+ In new patients presenting with suspected heart failure
in the outpatient setting, BNP testing is most useful as
a ‘rule-out’ test for heart failure.33
+ A clinical history should be taken and physical exam-
ination performed. If the BNP is below the decision
cut-point (‘normal’) then heart failure is very unlikely
and the patient should be investigated for other prob-
lems. If the BNP concentration is raised then there is a
strong possibility that the patient has heart failure for
which they should be fully investigated. This approach
is included in the guidelines of the European Society of
Cardiology Task Force for the Diagnosis and Treatment
of Chronic Heart Failure.33
+ For practical clinical purposes a ‘decision cut point’ of
100 pg/ml appears to provide optimum diagnostic ac-
curacy. If the BNP is <100 pg/ml in untreated patients,
then heart failure is highly unlikely. The decision
cut-points recommended in Europe for NT-proBNP are
100 pg/ml for males and 150 pg/ml for women, and in
the USA 125 pg/ml for both genders.
Patients presenting in the emergency care setting
+ In new patients presenting to emergency services with
dyspnoea, a history, physical examination and a chest
X-ray and ECG should be undertaken together with
laboratory measurements that include BNP testing.30
+ If the BNP is <100 pg/ml, then heart failure is highly
unlikely.
For patients with an existing diagnosis of heart failure
and who are taking many pharmacological agents
BNP testing may offer some help (particularly if a
baseline measurement is available) but such patients
are most likely to need a full cardiological assessment
in any case.
Screening for left ventricular systolic
dysfunction
After an acute myocardial infarction, plasma BNP con-
centration rises in proportion to the size of the infarct.34
It has been suggested that BNP measurement may have a
role in screening for left ventricular systolic dysfunction
in patients after myocardial infarction, and also in the
general population.
Among post-MI patients, plasma BNP concentrations
are inversely associated with ejection fraction.35,36 One
study compared plasma BNP concentrations with quanti-
tative and qualitative echocardiography, clinical evalu-
ation and a clinical scoring system in 75 patients who had
survived the first two days after an acute myocardial
infarction.37 A cut-off value of 15 pmol/l (52 pg/ml) gave
a sensitivity of 84% and a specificity of 62% for detecting
a left ventricular ejection fraction <40% on echo-
cardiography. However, other studies have been less
convincing.38,39
Similarly, there are inconclusive data for the role
of screening for asymptomatic left ventricular systolic
dysfunction in the general population.
In a community-based study of randomly selected
primary care subjects aged 25–74 years in Glasgow, a
plasma BNP concentration of 5.2 pmol/l (17.9 pg/ml) was
found to have a sensitivity of 76% and a specificity of 87%
for left ventricular systolic dysfunction as defined by an
EF ≤30% on echocardiography.40 In this population, in
which there was a relatively low prevalence of left ven-
tricular dysfunction, the positive predictive value was
only 16%, although at the chosen cut-point the negative
predictive value was 97.5%. Confining analysis to those
over 55 years of age increased the positive predictive
value to 32%.
Another primary care based study of subjects aged
70–84 years showed that those with echocardiographic
left ventricular systolic dysfunction had a higher plasma
BNP concentration than those with no evidence of sys-
tolic dysfunction (39.3 pmol/l vs 15.8 pmol/l); the area
under the ROC curve was high at 0.85.41 A cut-off point
of 18.7 pmol/l (64 pg/ml) gave 92% sensitivity and 65%
specificity for the diagnosis of left ventricular systolic
dysfunction with a negative predictive value of 99% but
with a positive predictive value of only 18%. The authors
concluded that a BNP measurement of less than
18.7 pmol/l (64 pg/ml) would rule out significant left
ventricular systolic dysfunction.
However, other studies have suggested BNP has a
limited diagnostic utility in identifying left ventricular
systolic dysfunction in the community.42,43 In part this
may be because plasma BNP concentrations are not
specific for left ventricular systolic dysfunction and the
degree of elevation of plasma concentration may be
much less marked in those who are asymptomatic.
Practical application
+ BNP testing is not appropriate for screening large
asymptomatic populations for left ventricular systolic
dysfunction
+ There may be some value in using plasma BNP to
screen high risk subgroups of the population such as
patients after MI, patients with diabetes or those with
chronic history of poorly controlled hypertension,
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although echocardiography is likely to remain the main
method of assessing left ventricular function in this
setting.
More work is needed with regard to screening before a
recommendation to change current practice can be
made.
BNP and NT-proBNP as prognostic indicators in
heart failure
BNP has been suggested as a means of identifying those
heart failure patients at high risk of death or hospital-
ization, in order to target therapy and enable selection
for tertiary or quaternary services.
Plasma BNP concentrations are higher in patients with
more severe symptoms and in those with more severe
cardiac damage.44 A raised BNP is able to differentiate
between moderate and severe impairment of left ven-
tricular function.45 In addition, BNP also correlates well
with cardiopulmonary exercise capacity and with com-
posite measures of heart failure severity, such as the
Heart Failure Survival Score.46
BNP is an independent predictor of death in patients
with chronic heart failure, and is superior to atrial natri-
uretic peptide (ANP) for predicting mortality.47 In this
study, each 10 pg/ml increase in plasma BNP was associ-
ated with a 3% increase in the risk of cardiac death over
the follow-up period. BNP is also an independent predic-
tor of all-cause mortality in patients with asymptomatic
or minimally symptomatic left ventricular dysfunction,
being superior to norepinephrine and left ventricular
volumes.48
In patients with acute heart failure, BNP has been
shown to be an independent predictor of cardiovascular
mortality,49 and is also predictive of outcome in patients
hospitalized with decompensated heart failure.50 Impor-
tantly, this last study suggested that measuring plasma
BNP concentrations before discharge may help to identify
patients with heart failure who are at a low risk of
re-admission within the next month (area under the ROC
curve 0.73).
Recent data in a small outpatient cohort with conges-
tive heart failure suggested that both BNP and NT-ANP
had predictive value for event-free survival to one
year.51
BNP may have a role in selecting patients with
advanced heart failure for transplantation. One recent
study looked at patients with severe left ventricular
function and heart failure. BNP concentrations were
the strongest predictor of mortality at four years of
follow-up.52 In an ambulant heart failure clinic popu-
lation, plasma BNP was at least equivalent to the
Heart Failure Survival Score (which is commonly used
for assessing patients for transplantation) in risk
stratification.46
It has been suggested that the more traditional
measures used to select patients for transplantation may
not be appropriate in the present beta-blocker era. For
instance, peak VO2 does not appear to have the same
prognostic value in patients on beta-blockers; this also
appears to be true for NT-proBNP, ejection fraction and
noradrenaline.53 However, recent data from Glasgow on
128 consecutive patients who were taking beta-blockers
and were awaiting transplantation show that the only
independent predictor of all cause mortality was an
NT-proBNP value above the median of 1498 pg/ml
(RR=4.6, P=0.01).54
A recent study looking at 452 ambulatory patients
with left ventricular dysfunction in whom there was a
high rate of sudden death found that the BNP concen-
tration was the only independent predictor of sudden
death.55
Practical application
In specialist centres, measurement of plasma BNP con-
centrations may prove a useful addition to clinical assess-
ment in situations where risk stratification is required,
for instance in selecting patients with advanced
heart failure for transplantation or for guiding referral
for device selection (implantable cardioverter-
defibrillators, resynchronization therapy and so on).
Further studies are needed to determine whether
measuring plasma BNP should be used as a stand-alone
test or in conjunction with scoring systems such as the
Heart Failure Survival Score. Similarly, further work is
needed to determine whether a single measurement is
sufficient to predict the patient’s prognosis or whether
the change in concentration over time and with treat-
ment provides more information.
BNP and NTproBNP in monitoring of patients
with heart failure
Plasma BNP concentrations are known to fall rapidly on
treatment of patients with heart failure.56,57 In the
clinic setting, patients whose functional status im-
proved between visits showed a statistically significant
reduction in plasma BNP concentration of about 50%;
other variables such as NT-proANP and ANP or ejection
fraction showed no statistically significant change.58
Pilot data have suggested that vasodilator treatment
can be titrated to reduce BNP concentrations towards
the normal range in patients with mild to moderate
heart failure.59
However, the monitoring of therapy by measuring
plasma BNP concentration is complicated by the wide
variation of plasma BNP levels reported in patients with
symptomatic heart failure, which may make titration to a
‘target’ dose of BNP difficult. Furthermore, recent
data show a progressive rise in a variety of natriuretic
peptides as patients’ renal function deteriorates.60
As yet it is unclear what reduction in creatinine
clearance is necessary for this effect appear; it may be
relatively modest but nevertheless has implications
for targeting of therapy. Reducing the plasma BNP
concentration in the clinical setting by stepping up the
diuretic dose may result in the patient developing
worsening renal function, which may offset the
expected reduction in BNP. Therefore, to titrate drugs
1714 M.R. Cowie et al.
against BNP is therefore not as simple an idea as it
first appears.
Nevertheless, there is some evidence of the possible
benefit of a BNP-guided approach to therapy (with
diuretics and ACE inhibitors) from a randomized trial
conducted in 69 patients with symptomatic heart failure
due to left ventricular systolic dysfunction.61 Half the
patients received therapy guided by plasma NT-proBNP
measurement; therapy in the remaining patients was
guided by clinical monitoring at the same frequency, but
with the physician blinded to the NT-proBNP result. Clini-
cal monitoring was based on scores assigned to 10 symp-
toms or signs of heart failure used in the Framingham
criteria for heart failure.
The study found significantly fewer total cardiovascu-
lar events (deaths, hospital admissions or episodes of
decompensation of heart failure) in the group random-
ized to NT-proBNP-guided therapy (target NT-proBNP
concentration 200 pmol/l [1680 pg/ml]) compared to a
similar group of patients in whom therapy was guided by
commonly used clinical variables (P=0.02). Both time to
first cardiovascular event and time to first heart failure
event or death were significantly delayed (P=0.034 and
P=0.049 respectively).
A larger study with a lower target NT-proBNP concen-
tration (100 pmol/l [840 pg/ml]) is now underway in
patients taking beta-blockers and spironolactone as well
as diuretics and ACE-inhibitors. This study (BATTLE-
SCARRED) may provide firmer evidence as to whether or
not NT-proBNP can be used as a biochemical surrogate
end-point in the monitoring of the treatment of patients
with heart failure due to left ventricular systolic dysfunc-
tion. In addition, the multicentre Rapid Assessment of
Bedside BNP in Treatment of Heart Failure (RABBIT) study
or the French multicentre study Suivi du Traitement dans
l’insuffisAnce caRdiaque Systolique (STARS) may provide
answers regarding the appropriate ‘target’ plasma BNP
concentration.
BNP may also find a role in guiding introduction of
therapy for patients with heart failure. One study con-
ducted in patients with chronic stable heart failure due
to left ventricular systolic dysfunction suggested that
the beta-blocker carvedilol was most efficacious in
patients with higher pre-treatment BNP concentrations
(above 24 pmol/l [82.5 pg/ml]).62 This hypothesis has
not been examined in a prospective randomized trial.
However, a similar finding for NT-proBNP has also been
reported.63 Further work is required before BNP
measurement can have a role in guiding the introduc-
tion of beta-blockade (and other therapies) in heart
failure.
Practical application
At present, there are too few data available to make a
firm recommendation regarding target BNP levels and
levels at which treatment should be altered. However,
rising BNP concentrations should alert the clinician to
decompensation. Regular monitoring of BNP may also
help to stratify the follow-up interval for more rational
planning of discharge and clinical review.
Panel—Ongoing studies of natriuretic peptides in
patients with heart failure
Study Title Aim Reporting
UKNPS United Kingdom
Natriuretic
Peptide Study
To determine
the clinical
utility of plasma
BNP and
NT-proBNP in
ruling out heart
failure (a
multi-centre
study)
2003
BATTLE-
SCARRED
BNP-Assisted
Treatment To
Lessen Serial
Cardiovascular
Readmissions
and Death
To compare
heart failure
management
guided by
NT-proBNP
measurements
with treatment
guided by
rigorous clinical
evaluation
2004
RABBIT Rapid
Assessment of
Bedside BNP in
Treatment of
Heart Failure
To determine
whether
utilization of
BNP at the
bedside provides
better guidance
of management
than standard
means
2004
STARS Suivi du
Traitement
dans
l’insuffisAnce
caRdiaque
Systolique.
Treatment
monitoring of
systolic cardiac
insufficiency
(dysfunction)
To compare
heart failure
management
guided by BNP
measurements
with treatment
guided by
clinical and
echocardiographic
evaluation
2004
Potential future uses of BNP and NTproBNP
testing
It is likely that the future will see a shift from the use of
BNP only in patients with heart failure to use also in other
cardiac disorders. Recent data suggest that BNP is the
best predictor of 30-day mortality in patients with acute
coronary syndromes64 while other workers have shown
that an NTproBNP level above the median value predicts
four-year mortality in acute coronary syndromes.65
Further work is required.
There may also be a potential for utilizing plasma BNP
concentrations in screening for left ventricular diastolic
dysfunction.
Some 20–50% of patients with the diagnosis of heart
failure have preserved systolic function on echocardiog-
raphy, with diastolic dysfunction as the most likely
potential cardiac abnormality.66,67 The proportion of
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patients with heart failure due to isolated diastolic ab-
normalities rises with age. In most cases, ‘diastolic’ heart
failure cannot be distinguished from ‘systolic’ heart fail-
ure on the basis of history, physical examination, chest
X-ray and ECG alone. Rather, the diagnosis of abnormal
diastolic performance is most often based on exclusion of
significant systolic dysfunction or valve disease in
patients with heart failure.
Lubien and colleagues measured plasma BNP levels in
294 patients referred for echocardiography other than
for assessment of abnormal systolic function, valve dis-
ease, possible endocarditis, or possible intracardiac
thrombus.68 Those patients with abnormal LV diastolic
function (n=119) had a mean plasma BNP concentration
of 286±31 pg/ml while the normal LV group (n=175) had a
mean BNP concentration of 33±3 pg/ml. Plasma concen-
trations were particularly elevated in patients with re-
strictive filling patterns and in those with symptoms. The
area under the ROC curve for the detection of any dia-
stolic dysfunction was 0.92 (95% CI 0.87–.95, P<0.001). A
BNP value of 62 pg/ml (18 pmol/l) gave a sensitivity
of 85%, specificity of 83% and an accuracy of 84% for
detecting isolated diastolic dysfunction.
Therefore, in patients with normal systolic left ven-
tricular function and no valve disease, an elevated
plasma BNP concentration is highly suggestive of clini-
cally significant diastolic dysfunction. This suspicion
should be even stronger if the Doppler examination is also
abnormal.
Conclusion
On the basis of current evidence, plasma BNP testing is of
most value in the diagnostic arena where it is likely to
improve the performance of non-specialist physicians in
diagnosing heart failure.
In clinical practice, BNP testing is best used as a ‘rule
out’ test for suspected cases of new heart failure in
breathless patients presenting to either the outpatient
and emergency care settings; it is not a replacement for
echocardiography and full cardiological assessment,
which will be required for patients with an elevated BNP
concentration. Although further work is ongoing in estab-
lishing the ‘normal’ values of BNP heart failure appears
to be highly unlikely below a plasma concentration of
100 pg/ml.
However, it should be remembered that BNP levels
rise with age and are affected by gender, comorbidity
and drug therapy. Therefore, the plasma BNP measure-
ment should not be used in isolation from the clinical
context.
For cardiologists, measurement of plasma BNP levels
may be helpful in guiding therapy and monitoring the
course of heart failure, particularly in alerting clinicians
to decompensation.
Measurement of BNP concentrations may also prove a
useful addition to clinical assessment in situations where
risk stratification is required, for instance in selecting
patients with advanced heart failure for transplantation
or for guiding referral for device selection in patients at
risk of sudden death. Further research will inform this
area.
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